The "KLOW" Peptide Blend: What's in the Vial, and What Isn't Tested

"KLOW" is a four-peptide research blend: GHK-Cu, BPC-157, TB-500, and KPV, freeze-dried together in a single vial and sold almost entirely through gray-market "research chemical" vendors. It is the most-searched peptide blend name that has almost nothing written about it honestly, and the reason is that the honest version is short: nobody has tested it.

This page answers the questions people actually type — what KLOW is, what's in it, what a dose would even mean, how it differs from GLOW, and whether a tested athlete can touch it. Two of those answers are unusually firm. The rest are unusually empty, and saying so is the point.

What KLOW Actually Is: GLOW, Plus KPV

The simplest accurate description is that KLOW is the GLOW blend with a fourth peptide added. GLOW is GHK-Cu + BPC-157 + TB-500, commonly sold as a 70 mg vial split 50/10/10. KLOW adds 10 mg of KPV to that same base, which is where the 80 mg vial and the extra letter both come from.

The composition printed by most vendors is consistent:

• •GHK-Cu — 50 mg. A copper-bound tripeptide (glycyl-L-histidyl-L-lysine), first isolated from human plasma. Five-eighths of the vial by mass.
• •BPC-157 — 10 mg. A 15-amino-acid sequence derived from a protein in gastric juice.
• •TB-500 — 10 mg. A synthetic fragment of thymosin beta-4.
• •KPV — 10 mg. A lysine-proline-valine tripeptide from the C-terminal tail of alpha-MSH.

A note on the name, because guide sites state it three different ways with equal confidence: KLOW is not an acronym. The K is KPV and the rest is GLOW; no source maps L, O, or W to anything, and the ones claiming a clean four-letter acronym cannot account for three of the four letters. It is a product name riffing on a product name.

"80 mg KLOW" Does Not Describe a Defined Product

This is the finding that matters most, and it is checkable rather than rhetorical.

Four vendors we read print the same 50/10/10/10 split for an 80 mg vial. But Luxe Peptides publishes a third-party certificate of analysis for its KLOW blend — Freedom Diagnostics, lot #2603300150, tested 31 March 2026 — and the numbers on that COA are not 50/10/10/10. They are GHK-Cu 30.55 mg, KPV 22.90 mg, BPC-157 18.54 mg, thymosin beta-4 9.96 mg⁹. That is a different product wearing the same name and the same "80 mg" label: 40% less GHK-Cu and more than twice the KPV than the split every other seller prints. The COA's own components also sum to 81.95 mg, not 80.

Sit with what that means for the most common KLOW search of all, which is a dosage chart. If you draw 15 units from an 80 mg KLOW vial reconstituted in 2 mL, you have drawn 6 mg of blend. How much of that is GHK-Cu? On one vendor's numbers, 3.75 mg. On another's published COA, 2.29 mg. You cannot know how much of any single active you injected without reading the certificate for the specific lot in your hand — and a chart written for "KLOW 80mg" cannot tell you, because the name does not fix the contents.

This is not a fringe complaint. It is precisely what the FDA's own scientific reviewers told the Pharmacy Compounding Advisory Committee about peptides generally in July 2026: that they could not define the substances chemically, because material sold under the same peptide name varies considerably¹¹. KLOW is that argument in a single vial. If you are going to buy from this market at all, the COA and third-party testing guide is the prerequisite, not an optional extra — and a single "99% pure" figure on a four-peptide blend is close to meaningless, since it never says which of the four it describes.

The price spread points the same way. The same nominal 80 mg KLOW vial was listed at $100, $140, $159.99, and $274.97 across four sellers on the same day. A near-threefold spread on an identical-sounding product is a sign that the product is not identical.

No Study Has Ever Tested This Combination

There is no published clinical trial, and no animal study, testing GHK-Cu, BPC-157, TB-500, and KPV administered together, at any ratio, for any outcome. Every citation a KLOW seller offers is borrowed from one of the four ingredients studied alone.

That borrowing is worth examining closely, because the individual literatures are real but they do not point where the marketing points:

• •GHK-Cu has genuine tissue-remodeling and gene-modulation work behind it, much of it from one research group¹, plus rat wound studies showing increased connective tissue accumulation². Its human data is topical — skin, applied to the surface. We cover this in detail in GHK-Cu for recovery and skin.
• •BPC-157 has an extensive rodent wound- and tendon-healing literature³, and a 2026 biopharmaceutical review searching the regulatory databases directly concluded its development remains rudimentary, with no approved formulation and no validated dosing regimen⁴. There is no human dosing trial. See the BPC-157 recovery evidence.
• •TB-500 rests on thymosin beta-4's actin-sequestering and angiogenesis mechanism, studied largely in isolation and largely preclinically⁵. See TB-500 for recovery.
• •KPV is the one whose evidence is most often misread. Its strongest work is intestinal: PepT1-mediated uptake reducing colitis in mice⁶, and orally delivered nanoparticle formulations alleviating ulcerative colitis in animal models⁷. That is a gut-lumen story, told through oral and targeted delivery. Our KPV evidence review walks through it.

Notice the pattern. Three of the four components have their most meaningful evidence in a route the blend does not use. GHK-Cu's human data is topical; KPV's is oral and gut-targeted; BPC-157's is rodent, often oral or intraperitoneal. KLOW is sold to be injected subcutaneously. Injecting a compound whose evidence came from a skin cream, or from a nanoparticle engineered to survive the stomach and release in the colon, is not "the same molecule, different route" — the delivery was the finding in several of those studies.

And "combination" is not "synergy." Synergy is a specific, testable pharmacological claim — that the combined effect exceeds the sum of the parts — and it requires a study built to isolate that interaction. Putting four peptides in one vial and calling the result synergistic is an inference drawn from a packaging decision. Nothing rules out interference, or degradation of one component by another during storage and reconstitution, because nobody has looked.

KLOW Contains No Larazotide — That's a Different Product

A persistent piece of misinformation has KLOW containing larazotide. It does not. Not one KLOW product page lists it, and the confusion is worth clearing up because the real larazotide product is a genuinely different thing sold for a different reason.

Larazotide (larazotide acetate, AT-1001) is a zonulin antagonist that regulates intestinal tight junctions. It shows up in oral capsule blends — typically stable BPC-157 arginate + KPV + larazotide, sold as "gut inflammation" formulas — and it is oral by design, because it acts in the gut lumen and is not meant to be absorbed. At least one vendor sells that capsule product and a "KLOW Blend" as two separate SKUs.

Larazotide also has something none of KLOW's four components has: a real, completed, published human efficacy trial. A phase II randomized controlled trial in patients with persistent celiac symptoms despite a gluten-free diet was published in Gastroenterology in 2015⁸. What happened next is the part that never appears in the marketing. The phase 3 trial — NCT03569007, 307 participants, run from May 2019 — was terminated by its sponsor, with the registry recording the reason simply as "Trial terminated by Sponsor"¹⁰. Larazotide has never been approved for anything, anywhere.

So the compound with the strongest human record in this whole neighborhood is one that KLOW does not contain, is taken orally rather than injected, and failed to finish phase 3.

Dosage: There Isn't One

There is no established dose for KLOW, because establishing a dose requires trials that do not exist. What circulates instead is a spread of protocols that disagree with each other by roughly an order of magnitude — from around 500 mcg of total blend per injection at one end to several milligrams at the other. One clinic selling it declines to publish a figure at all.

We are not going to add a number to that pile. What we will say is arithmetic, which is the only part of this that is knowable: if you want to understand what a given volume represents for a given vial and a given amount of bacteriostatic water, our peptide reconstitution and dose calculator does the unit conversion — vial mg ÷ water mL gives concentration, amount ÷ concentration gives volume, volume × 100 gives U-100 syringe units. It proposes no dose, and for KLOW it cannot tell you the per-component amounts anyway, for the reason set out above: the name does not fix the split.

Every KLOW vendor we read labels the product research use only and not for human consumption — "not for human consumption, clinical use, veterinary applications, or any diagnostic or therapeutic purposes" is representative wording. Several of those same sites publish weekly human injection schedules and injection-site advice on the page below the disclaimer. That contradiction is the market's normal operating state, not an anomaly, and it is worth reading alongside our guide to peptide vendor red flags.

Anti-Doping: Two of the Four Are Banned Outright

If you are drug-tested, this section is the only one you need.

BPC-157 is prohibited at all times under WADA class S0, the category for substances with no approved human therapeutic use anywhere. TB-500 is prohibited at all times as well, captured by S0 and by the S2 growth-factor family. Both statuses are unchanged by the 2026 List and unchanged by any US compounding development — a domestic regulatory shift and an anti-doping classification are separate things.

That settles it: a KLOW vial contains two substances that are banned year-round, so KLOW is banned year-round, whatever the other two do.

On those other two — GHK-Cu and KPV are not named entries on the list our WADA status checker draws from, and that is not the same as permitted. S0 is defined by a property, not by a roll call: it covers any pharmacological substance with no current regulatory approval for human therapeutic use. Neither GHK-Cu nor KPV has a marketing authorization anywhere. Reading "not named" as "allowed" is the specific mistake S0 exists to prevent.

Legal Status: Four Components, No Lawful Basis

One vial, and its contents do not even share a regulatory position. At the July 23–24, 2026 PCAC meeting, three of KLOW's four components were reviewed and each cleared 8–6 with one abstention — BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing¹¹¹². GHK-Cu was not before the committee at all.

The single sentence that matters: a PCAC recommendation is not permission. The votes are advisory and non-binding, and final rulemaking must be in place before any pharmacy may lawfully compound these substances. None of the four is on the 503A bulk drug substances list today, so none may legally be compounded in the US — and none of the uses evaluated was athletic recovery, tendon repair, or performance, which is what KLOW is actually sold for.

The full account of the meeting is in what actually happened at the FDA peptide advisory vote, and the component-level detail in KPV's FDA status.

Bottom Line

KLOW is a packaging decision with a memorable name: the GLOW blend plus KPV, sold as an 80 mg vial by sellers who do not agree on what the 80 mg is made of. No study has tested the combination. Three of its four components have their best evidence in a route the blend does not use. Two of the four are prohibited at all times in tested sport, which makes the blend prohibited. And the compound most often wrongly attributed to it — larazotide — is an oral drug whose phase 3 was terminated.

None of that makes the individual ingredients fake. GHK-Cu, BPC-157, TB-500, and KPV each have a real, limited, mostly-preclinical literature, and we review each one separately. It does mean the specific claim on offer — that this vial, at this ratio, produces the healing and anti-inflammatory results advertised — is untested, and that the vial you receive may not match the vial the last person reviewed. If you are weighing the three-peptide version instead, the same analysis applies one component earlier in the GLOW blend, and the two-peptide case is covered in BPC-157 and TB-500 as a stack.